Bavarian Nordic
NEWS
Bavarian Nordic announced the U.S. Biomedical Advanced Research and Development Authority has ordered an additional 500,000 doses of its monkeypox vaccine, Jynneos.
Zabdeno, a two-dose heterologous vaccine, was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all participants.
A paper discussing recent preclinical advances of Bavarian Nordic’s novel cancer immunotherapy platform was published in the prominent, peer-reviewed, open access journal, Nature Communications.
Bavarian Nordic A/S announced that the U.S. Food and Drug Administration has approved JYNNEOS™ for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
Bavarian Nordic A/S announced the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN® smallpox vaccine in 1,110 healthy, vaccinia-naïve subjects.
Bavarian Nordic A/S announced that the Data and Safety Monitoring Board confirmed a partial response in one of the first chordoma patients recruited and treated with the combination of BN-Brachyury and radiation treatment at the first evaluation timepoint.
Bavarian Nordic A/S today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for the liquid-frozen version of the MVA-BN®for active immunization against smallpox in adults age 18 years and older.
Award of approximately USD 37 million will support clinical work required for product approval.
JOBS
IN THE PRESS